References
Original article
Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.22.01725 (2022)
Related article
Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220–2231 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Epcoritamab is active in large B cell lymphomas. Nat Rev Clin Oncol 20, 138 (2023). https://doi.org/10.1038/s41571-023-00730-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00730-9
- Springer Nature Limited